Brazilian health-care policy for targeted oncology therapies and companion diagnostic testing

The Lancet Oncology

Volumn 17, Issue 8, 2016, Pages e363-e370

  Ferreira, Carlos Gil ^a   Achatz, Maria Isabel ^b   Ashton Prolla, Patricia ^c,d   Begnami, Maria Dirlei ^b   Marchini, Fabricio K ^e   Stefani, Stephen Doral ^f  

^a D OR INSTITUTE FOR RESEARCH AND EDUCATION IDOR   (Brazil)

^b A C CAMARGO CANCER CENTER   (Brazil)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^d FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^e INSTITUTO CARLOS CHAGAS   (Brazil)

^f Diagnostic Imaging Department   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER THERAPY; CLINICAL EFFECTIVENESS; DIAGNOSTIC TEST; GENETIC SCREENING; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HUMAN; MEDICAL EDUCATION; PATIENT IDENTIFICATION; PERSONNEL SHORTAGE; PRIORITY JOURNAL; PUBLIC-PRIVATE PARTNERSHIP; REIMBURSEMENT; REVIEW; ANTAGONISTS AND INHIBITORS; HEALTH CARE DELIVERY; LEGISLATION AND JURISPRUDENCE; METABOLISM; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; PERSONALIZED MEDICINE; STANDARDS;

ANTINEOPLASTIC AGENT; TUMOR PROTEIN;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DELIVERY OF HEALTH CARE; HEALTH POLICY; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASMS; PRECISION MEDICINE;

EID: 84995922908     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30171-1     Document Type: Review

References (28)

1. 1 Ocaña, A, Pandiella, A, Personalized therapies in the cancer “omics” era. Mol Cancer, 9, 2010, 202.
2. 2 Simon, R, Clinical trials for predictive medicine: new challenges and paradigms. Clin Trials 7 (2010), 516–524.
3. 3 Tefferi, A, Kantarjian, H, Rajkumar, SV, et al. In support of a patient-driven initiative and petition to lower the high price of cancer drugs. Mayo Clin Proc 90 (2015), 996–1000.
4. 4 Lièvre, A, Bachet, JB, Le Corre, D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66 (2006), 3992–3995.
5. 5 Van Cutsem, E, Köhne, CH, Hitre, E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360 (2009), 1408–1417.
6. 6 Rubin, EH, Allen, JD, Nowak, JA, Bates, SE, Developing precision medicine in a global world. Clin Cancer Res 20 (2014), 1419–1427.
7. 7 Mansfield, EA, FDA perspective on companion diagnostics: an evolving paradigm. Clin Cancer Res 20 (2014), 1453–1457.
8. 8 Farhat, FS, Houhou, W, Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?. Ther Adv Med Oncol 5 (2013), 249–270.
9. 9 Slater, J, Shields, L, Racette, RJ, Juzwishin, D, Coppes, M, The emergence of precision therapeutics: new challenges and opportunities for Canada's health leaders. Healthc Manage Forum 28:suppl (2015), S33–S39.
10. 10 Risch, HA, McLaughlin, JR, Cole, DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68 (2001), 700–710.
11. 11 Struewing, JP, Hartge, P, Wacholder, S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336 (1997), 1401–1408.
12. 12 Pruthi, S, Gostout, BS, Lindor, NM, Identification and management of women with BRCA mutations or hereditary predisposition for breast and ovarian cancer. Mayo Clin Proc 85 (2010), 1111–1120.
13. 13 Livraghi, L, Garber, JE, PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med, 13, 2015, 188.
14. 14 Kazan, O, The struggle of universal healthcare. The Atlantic Website. www.theatlantic.com/health/archive/2014/05/the-struggle-for-universal-healthcare/361854/, May 8, 2014 (accessed May 8, 2016).
15. 15 Fink, A, Kosecoff, J, Chassin, M, et al. Consensus methods: characteristics and guidelines for use. Am J Public Health 74 (1984), 979–983.
16. 16 Waggoner, J, Carline, JD, Durning, SJ, Is there a consensus on consensus methodology? Descriptions and recommendations for future consensus research. Acad Med 91 (2016), 663–668.
17. 17 Fleck, LM, “Just caring”: can we afford the ethical and economic costs of circumventing cancer drug resistance?. J Pers Med 3 (2013), 124–143.
18. 18 Dzau, VJ, Ginsburg, GS, Van Nuys, K, Agus, D, Goldman, D, Aligning incentives to fulfil the promise of personalized medicine. Lancet 385 (2015), 2118–2119.
19. 19 Garrison, LP Jr, Rewarding value creation to promote innovation in oncology: the importance of considering the global product life cycle. Oncologist 15:suppl 1 (2010), 49–57.
20. 20 Canuto Santos VC. As análises econômicas na incorporação de tecnologias em saúde: reflexões sobre a experiência brasileira. Masters dissertation, Escola Nacional de Saúde Pública, Fundação Oswaldo Cruz, 2010: 132.
21. 21 Akhmetov, I, Bubnov, RV, Assessing value of innovative molecular diagnostic tests in the concept of predictive, preventive, and personalized medicine. EPMA J, 6, 2015, 19.
22. 22 Barrios, PM, Debiasi, M, Lopes, G, Barrios, C, Impact of regulatory delays in approving oncology drugs in a developing country: mortality associated with lack of access to crizotinib in Brazil. J Thorac Oncol, 10(suppl 2), 2015, S227.
23. 23 WHO. Global Health Observatory (GHO) data. Brazil: country profiles. www.who.int/gho/countries/bra/country_profiles/en/, 2015 (accessed Nov 18, 2015).
24. 24 Lee, BL, Liedke, PE, Barrios, CH, Simon, SD, Finkelstein, DM, Goss, PE, Breast cancer in Brazil: present status and future goals. Lancet Oncol 13 (2012), e95–102.
25. 25 Ferreira, CG, Lung cancer in developing countries: access to molecular testing. Dizon, DS, (eds.) American Society of Clinical Oncology Educational Book, 2013, American Society of Clinical Oncology, Alexandria, VA, 327–331.
26. 26 Slavik, T, Asselah, F, Fakhruddin, N, et al. Diagnosis and predictive molecular analysis on non-small-cell lung cancer in Africa-Middle East region: challenges and strategies for improvement. Clin Lung Cancer 15 (2014), 398–404.
27. 27 Rehman, A, Awais, M, Baloch, NU, Precision medicine and low- to middle-income countries. JAMA Oncol 2 (2016), 293–294.
28. 28 Tekola-Ayele, F, Rotimi, CN, Translational genomics in low- to middle-income countries: opportunities and challenges. Public Health Genomics 18 (2015), 242–247.